A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of JNJ-67953964 in Subjects With Major Depressive Disorder
Phase of Trial: Phase II
Latest Information Update: 16 Jan 2019
At a glance
- Drugs JNJ-67953964 (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 21 Sep 2018 Planned End Date changed from 11 Nov 2019 to 19 Nov 2019.
- 06 Aug 2018 Status changed from not yet recruiting to recruiting.
- 29 Jun 2018 Planned initiation date changed from 15 Jun 2018 to 9 Jul 2018.